Canada markets open in 4 hours 13 minutes

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.1800+0.0200 (+1.72%)
At close: 04:00PM EDT
1.1619 -0.02 (-1.53%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.1600
Open1.1800
Bid1.0100 x 2200
Ask1.2500 x 4000
Day's Range1.1600 - 1.2500
52 Week Range0.8400 - 1.6100
Volume705,131
Avg. Volume969,356
Market Cap222.782M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateAug 08, 2024 - Aug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.20
  • Business Wire

    Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    CARLSBAD, Calif., May 09, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

  • Business Wire

    OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

    CARLSBAD, Calif., May 06, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cel

  • Business Wire

    Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

    CARLSBAD, Calif., May 02, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific T